Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.33 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16854554 | 0.83 | CA14 (0.35) | CTSKCA14PDK2CACNA1GCACNA1B | |
| SCHEMBL16854646 | 0.83 | CA14 (0.35) | CTSKCA14PDK2CACNA1GCACNA1B | |
| SCHEMBL15866143 | 0.81 | CTSK (0.40) | CTSKCA14PDK2CACNA1GCACNA1B | |
| SCHEMBL3711368 | 0.81 | CTSK (0.38) | CTSKCA14PDK2CACNA1GCACNA1B | |
| SCHEMBL25690055 | 0.81 | CTSK (0.41) | CTSKCA14PDK2CACNA1GCACNA1B | |
| SCHEMBL16854489 | 0.80 | PKM (0.45) | CTSKCA14PDK2CACNA1GCACNA1B | |
| SCHEMBL16854480 | 0.80 | PKM (0.45) | CTSKCA14PDK2CACNA1GCACNA1B | |
| SCHEMBL25113381 | 0.79 | CTSK (0.38) | CTSKCA14PDK2CHRNB2CHRNB4 | |
| SCHEMBL16941095 | 0.79 | CTSK (0.39) | CTSKCA14PDK2CHRNB2CHRNB4 | |
| SCHEMBL754325 | 0.78 | CTSK (0.37) | CTSKCA14PDK2CHRNB2CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7119109-B2 | Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase | ASTRAZENECA AB (SE) | 2006-10-10 | — | — | US | disclosed |
| US-20040220234-A1 | Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase | ASTRAZENECA AB (SE) | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220234-A1 | Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase | NOS3, NOS2, NOS1 | CTSK 2319/4885CA14 4881/4885PDK2 3016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.